Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STS Gel for Cisplatin-Induced Ototoxicity
NCT02281006Phase 2Terminated
- Sponsor
- CHU de Québec-Université Laval
- Start
- Jan 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of sodium thiosulfate in cisplatin-induced ototoxicity (2 arms), sponsored by CHU de Québec-Université Laval. Primary endpoint: Hearing loss at high frequencies. Started Jan 2015; status: terminated.
02
Drugs
sodium thiosulfate
03
Conditions
cisplatin-induced ototoxicity
Beyond the preview
Go deeper on NCT02281006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281006.